Pintex Pharmaceuticals Inc

Adnexus, a Bristol-Myers Squibb R&D company, is situated at 100 Beaver St in Waltham, Massachusetts, within Middlesex County. The company specializes in providing pharmaceutical containers and equipment supplies, catering to the needs of the medical field. Dedicated to enhancing pharmaceutical operations, Adnexus strives to ensure quality and efficiency in their products and services. Clients can share their experiences and reviews to aid others in finding valuable resources within the pharmaceutical industry. Generated from the website

KALA BIO is a clinical-stage biopharmaceutical company based in Waltham, MA, dedicated to addressing rare and serious eye diseases through innovative therapies. Utilizing their proprietary mesenchymal stem cell secretome (MSC-S) platform, the company aims to develop regenerative treatments to preserve vision and improve patient outcomes. The firm is currently advancing its pipeline with therapies like KPI-012, a topical treatment for persistent corneal epithelial defect (PCED), and KPI-014, an intravitreal therapy for inherited retinal diseases. With a strong focus on biologics following the sale of its commercial products, KALA BIO is committed to making significant advancements in ophthalmic care. Generated from the website

Senesco Technologies is engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Its platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. The company is developing its technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. It is also researching applications of its technologies that may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma and cardiovascular disease. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.